EquipNet, Inc.
MarketPlace  |   Auctions  |   Tech Solutions  |   Appraisals  |   My EquipNet  |   Services



Blog

September 1, 2015
by Jessica Hamelburg
Comments Off

Appraisals: The Value of Equipment

Appraisals_CalculatorValue encompasses marketability, serviceability, utility and raw material salvage. All four of these factors change based on the business and technology. The value of equipment can be viewed as a capital resource with which to run operations more efficiently, a savings account to be tapped when needed or excess capital to be sold for cash. In any case, asset valuations, whether for asset-based lending or sale, require the expertise of certified appraisers to assure fair pricing. In specialty applications such as Small Business Administration loans, certified valuations may be required documentation.
 
What is Asset-Based Lending?
 
Asset-based lending leverages business equipment values against loans as a financial tool to balance cash and equity needs. It means using asset values to expand business or become liquid in leaner times.
 
Why is it Important?
 
Tying proper financing to the business need anticipates the asset repaying the loan through production. Borrowing money to build an efficient plant anticipates greater efficiency and profits, which repay the financing. Expanding business operations through financing tied to equipment makes the same promise: The equipment will repay the loan through efficiency and greater productivity. Every business encounters these decisions. How long will these efficiencies last compared to the competition? Can the new equipment pay for itself in this time frame?
 
Lenders require certified valuations in order to meet their regulatory requirements. They must show the loan is safe and collateralized. Companies seeking loans can make the banker’s job easier by anticipating this need and making appraisals part of the loan request package. It helps to plan the financing program, too.
 
Specialists such as EquipNet offer appraisal services on a spectrum of business assets, including:
 
   1. Machinery and equipment
   2. Real estate
   3. Deconstruction
   4. Price opinions
   5. Business valuations
   6. Inventories
 
Each appraisal has a specific purpose:
 
   • Financing
   • Financial Reporting
   • Litigation & Legal Support
   • Insurance & Risk Management
   • Taxation
   • Business Planning
 
EquipNet understands the subtle differences and assigns the correct expert to the valuation. Business finance can be complex, but understanding how money reflects future income or current asset value determines the smart management move. EquipNet guides this understanding by providing accurate market information with which to crunch the numbers.
 
EquipNet hires experts in diverse industries who know the state-of-the-art equipment in each target business. These experts anticipate the changes and directions within their expertise that will affect value. The benefit to using such experts is that the business owner can review the hard numbers and make a value decision before negotiating with a lender. If you want to use equipment financing as a tool for profit rather than wearing a loan like chains for the bank, proper planning and expert knowledge is the key.
 
Appraisals are offered for many industries through EquipNet, including but not limited to:
 
   • Chemical
   • Consumer Products
   • Pharmaceutical & Biotech
   • Medical Devices & Healthcare
   • Industrial Equipment
   • Technology & Electronics
   • Finance & Insurance
   • Government Services
   • Real Estate
   • Legal & Professional Services
 
EquipNet will help the business make realistic, solid decisions. EquipNet keeps an eye on balancing cash needs (liquidity) with production needs (hard assets), and income and expense outcomes when equipment or assets are financed. Let EquipNet help.


Share:
Share on FacebookTweet about this on TwitterShare on LinkedInEmail to someoneGoogle+

August 28, 2015
by Jessica Hamelburg
Comments Off

An Inside Look at On-site Hard Drive Destruction

 

 
Do you have old or unused hard drives that you need to safely destruct? EquipNet Technology Solutions offers onsite services to safely destroy surplus hard drives in the security of your own facility or data center.
 
Trust the hard drive destruction experts at EquipNet Technology Solutions and contact us today to schedule an appointment:
 

Ben Schugar
BSchugar@EquipNet.com
1.781.401.8160

 
Secure yesterday’s data while protecting tomorrow’s environment.

- EquipNet Technology Solutions


Share:
Share on FacebookTweet about this on TwitterShare on LinkedInEmail to someoneGoogle+

August 24, 2015
by Jessica Hamelburg
Comments Off

This Week: Lab and Pharma Equipment Auction

ONLINE AUCTION – Wednesday, August 24th, 2015

 
EquipNet will be hosting an online auction this Wednesday, August 24 featuring Lab and Pharmaceutical equipment in various locations across the US. The auction includes a range of Laboratory, Analytical and BioProcessing equipment from Sanofi, Bayer Healthcare & other leading global firms.
 

FEATURING:

200+ lots, including Micromeritics Analyzers, Profill Capsule Fillers, B. Braun Biotech Fermentors, Agilent Technologies Micro Array Scanners, Lee Industries Mixing Tanks and much more!
 
Inventory also includes Microscopes, Pumps, Refrigerators, Clean Rooms, Balances/Scales, Centrifuges and many other assets.
 
OEMs for these assets include Tektronix, Perkin Elmer, Waters, Honeywell and many others.
 

CLICK HERE TO REGISTER NOW!

 
registernow_8.24.15
 


Share:
Share on FacebookTweet about this on TwitterShare on LinkedInEmail to someoneGoogle+

August 19, 2015
by Jessica Hamelburg
Comments Off

Global Trends in the API Market

The global Active Pharmaceutical Ingredients (API) market will likely reach 185.9 billion USD by 2020, according to July 2015 estimates by Transparency Market Research, expanding at a CAGR of 6.5 percent between 2014 and 2020.
 
The global active pharmaceutical market is made up of several segments, which are categorized by therapeutic area. API segments include cancer drugs, non-steroidal anti-inflammatory drugs (NSAIDs), cardiovascular drugs, anti-diabetic drugs, musculoskeletal drugs, central nervous system drugs and others.
 
The Transparency Market Research report expects the overall API market to experience substantial growth between 2014 and 2020. The oncology and central nervous system drug segments will likely grow at the highest CAGR during that forecast period. Due to international prevalence of cardiovascular disease, increasingly sedentary lifestyles and aging population, cardiovascular drugs took the largest market revenue share in 2013.
 
Many blockbuster cancer drugs, such as Roche’s Herceptin and Xeloda, Celgene’s Abraxane and Vidaza, Arimidex by AstraZeneca and Temodar from Merck & Co., lost patent protection between 2010 and 2014. This created a void for other oncology drug makers to enter the API market.
 
Loss of market exclusivity by bestselling products continues to be a common trend in all segments of the API market, thereby creating new opportunities for makers of generic products. In turn, this will boost demand for APIs in certain segments.
 
Biosimilar drugs are opening up the highly regulated U.S. market to further stimulate overall API market growth. In 2015, filgrastim was the first biosimilar drug to gain approval in the United States. Biological drugs are increasingly important for the treatment of certain chronic diseases, such as diabetes and cancer. Challenging manufacturing requirements and difficult replication make these drugs costlier. Production technology advancements have enabled the production of biosimilars, which are not exact copies of innovator drugs but do offer comparable safety and efficacy. Europe is energetically approving biosimilars; WHO has adopted biosimilar guidelines similar to those used by the European Union. Marketing opportunities for biopharmaceutical companies will increase as nations develop regulatory pathways to handle biosimilars.
 
Cancer is one of the leading causes of illness and death worldwide, according to the World Health Organization (WHO), with 14 million new cases and 8.2 cancer-related deaths in 2012. WHO expects the number of new cases to rise 70 percent over the next 20 years. This rapid increase in cancer cases will cause oncology to be the fastest growing segment in the API market. Furthermore, the majority of drugs in the oncology segment contain at least one High Potency Active Pharmaceutical Ingredient (HPAPI), another rapidly growing segment of this global market.
 
The development of HPAPI and biogeneric drugs will boost API market growth. The shift to low-cost API drugs after the economic recession had a positive effect on the overall growth of the API market. Various novel technologies helped API manufacturers reduce processing time and increase yield. Valued at $8,900 million in 2011, MarketsandMarkets predicts the global HPAPI market to grow at a CAGR of 8.3 percent until 2016.


Share:
Share on FacebookTweet about this on TwitterShare on LinkedInEmail to someoneGoogle+